Gyre Therapeutics, Inc. (GYRE) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
46.38
↓-20% vs avg
5yr avg: 58.15
30Y Low49.4·High69.2
P/FCF
↓
N/A
—
5yr avg: 101.84
30Y Low88.8·High122.8
P/B Ratio
↓
5.13
↓-84% vs avg
5yr avg: 31.49
30Y Low5.1·High130.5
ROE
↑
4.2%
↓+106% vs avg
5yr avg: -67.2%
30Y Low-216%·High22%
Debt/EBITDA
↑
0.07
↓-7% vs avg
5yr avg: 0.07
30Y Low0.1·High3.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GYRE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Gyre Therapeutics, Inc. trades at 314.2x earnings, 15% above its 5-year average of 273.6x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 1308%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $686M | $728M | $1.2B | $1.7B | $602M | $418M | $1.8B | $1.2B | $1.3B | $701M | $114M |
| Enterprise Value | $650M | $692M | $1.2B | $1.7B | $577M | $376M | $1.8B | $1.2B | $1.3B | $691M | $123M |
| P/E Ratio → | 314.22 | 313.78 | 242.00 | — | 265.00 | — | — | — | — | — | — |
| P/S Ratio | 5.88 | 6.25 | 11.70 | 14.91 | 5.88 | 57.00 | 86.66 | — | 221193.86 | 688.14 | 285.46 |
| P/B Ratio | 5.13 | 5.12 | 12.58 | 121.24 | 8.33 | 10.18 | 23.86 | 17.94 | 11.06 | 22.76 | 7.09 |
| P/FCF | — | — | — | 97.72 | 105.95 | — | — | — | — | — | — |
| P/OCF | 678.96 | 721.24 | — | 65.32 | 56.36 | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
GYRE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Gyre Therapeutics, Inc.'s enterprise value stands at 46.4x EBITDA, 20% below its 5-year average of 58.1x. The Healthcare sector median is 14.4x, placing the stock at a 222% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.94 | 11.61 | 14.62 | 5.64 | 51.28 | 85.29 | — | 215991.70 | 678.92 | 308.36 |
| EV / EBITDA | 46.38 | 49.43 | 69.15 | — | 55.86 | — | — | — | — | — | — |
| EV / EBIT | 56.55 | 60.25 | 75.64 | 86.30 | 62.71 | — | — | — | — | — | — |
| EV / FCF | — | — | — | 95.81 | 101.63 | — | — | — | — | — | — |
GYRE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Gyre Therapeutics, Inc. earns an operating margin of 9.9%. Operating margins have expanded from -59.3% to 9.9% over the past 3 years, signaling improving operational efficiency. ROE of 4.2% is modest. ROIC of 8.9% represents adequate returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.4% | 95.4% | 96.3% | 95.9% | 95.3% | -4.5% | 56.3% | — | -357800.0% | -1162.0% | -2545.4% |
| Operating Margin | 9.9% | 9.9% | 15.3% | -59.3% | 9.0% | -1141.0% | -273.9% | — | -563700.0% | -2143.6% | -5117.3% |
| Net Profit Margin | 4.3% | 4.3% | 11.4% | -81.9% | 2.3% | -1198.3% | -265.1% | — | -500916.7% | -2118.0% | -4246.9% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.2% | 4.2% | 21.5% | -215.7% | 4.1% | -150.1% | -76.9% | -58.6% | -39.9% | -92.1% | -71.4% |
| ROA | 3.4% | 3.4% | 10.0% | -92.3% | 3.3% | -116.8% | -57.4% | -49.4% | -36.6% | -55.6% | -31.5% |
| ROIC | 8.9% | 8.9% | 35.1% | -353.8% | 29.5% | -270.2% | -84.3% | -59.9% | -46.1% | -70.2% | -50.0% |
| ROCE | 9.1% | 9.1% | 16.0% | -79.6% | 16.1% | -141.3% | -78.2% | -60.4% | -44.8% | -93.1% | -85.3% |
GYRE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Gyre Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.1x, which is very conservative (98% below the sector average of 3.3x). The company holds a net cash position — cash of $37M exceeds total debt of $939000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.06 | 0.02 | 0.03 | — | 0.17 | 1.21 |
| Debt / EBITDA | 0.07 | 0.07 | 0.09 | — | 0.06 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.25 | -0.10 | -2.37 | -0.34 | -1.02 | -0.38 | -0.20 | -0.26 | -0.31 | 0.57 |
| Net Debt / EBITDA | -2.58 | -2.58 | -0.58 | — | -2.38 | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -1.91 | -4.33 | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($37M) exceeds total debt ($939000)
GYRE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Gyre Therapeutics, Inc.'s current ratio of 5.60x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 5.04x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.85x to 5.60x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.60 | 5.60 | 3.32 | 2.85 | 4.06 | 3.63 | 5.03 | 3.32 | 25.83 | 4.48 | 1.71 |
| Quick Ratio | 5.04 | 5.04 | 2.99 | 2.64 | 3.56 | 3.63 | 5.03 | 3.32 | 25.83 | 3.87 | 0.82 |
| Cash Ratio | 2.87 | 2.87 | 1.37 | 1.67 | 2.06 | 3.31 | 4.46 | 2.66 | 25.02 | 3.71 | 0.78 |
| Asset Turnover | — | 0.70 | 0.84 | 0.97 | 1.21 | 0.13 | 0.22 | — | 0.00 | 0.03 | 0.01 |
| Inventory Turnover | 0.53 | 0.53 | 0.61 | 1.08 | 0.78 | — | — | — | — | 2.42 | 0.54 |
| Days Sales Outstanding | — | 115.67 | 100.62 | 54.18 | 55.72 | 90.43 | 57.73 | — | — | 8.61 | 28.36 |
GYRE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Gyre Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | 0.6% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.3% | 0.3% | 0.4% | — | 0.4% | — | — | — | — | — | — |
| FCF Yield | — | — | — | 1.0% | 0.9% | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.6% | 0.0% |
| Shares Outstanding | — | $103M | $102M | $66M | $76M | $31M | $19M | $12M | $11M | $3M | $778780 |
Peer Comparison
Compare GYRE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GYREYou | $686M | 314.2 | 46.4 | — | 95.4% | 9.9% | 4.2% | 8.9% | 0.1 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ARDX | $2B | -26.8 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 IDYA | $2B | -22.1 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 TGTX | $7B | 15.5 | 57.1 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
See GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GYRE vs HALO
Side-by-side business, growth, and profitability comparison vs Halozyme Therapeutics, Inc..
Start ComparisonGYRE — Frequently Asked Questions
Quick answers to the most common questions about buying GYRE stock.
What is Gyre Therapeutics, Inc.'s P/E ratio?
Gyre Therapeutics, Inc.'s current P/E ratio is 314.2x. This places it at the 50th percentile of its historical range.
What is Gyre Therapeutics, Inc.'s EV/EBITDA?
Gyre Therapeutics, Inc.'s current EV/EBITDA is 46.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 58.1x.
What is Gyre Therapeutics, Inc.'s ROE?
Gyre Therapeutics, Inc.'s return on equity (ROE) is 4.2%. The historical average is -45.2%.
Is GYRE stock overvalued?
Based on historical data, Gyre Therapeutics, Inc. is trading at a P/E of 314.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Gyre Therapeutics, Inc.'s profit margins?
Gyre Therapeutics, Inc. has 95.4% gross margin and 9.9% operating margin.
How much debt does Gyre Therapeutics, Inc. have?
Gyre Therapeutics, Inc.'s Debt/EBITDA ratio is 0.1x, indicating low leverage. A ratio below 2x is generally considered financially healthy.